Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Two new observational studies shed light on how hormone replacement therapy (HRT) affects cardiovascular risk in menopausal women. Starting HRT within 10 years of menopause appears protective, oral formulations carry higher clot and stroke risks than transdermal options, and racial differences matter too. Experts say personalized decision-making—not a one-size-fits-all approach—is the way forward.
Two new observational studies are adding important nuance to the long-running debate over hormone replacement therapy (HRT) and cardiovascular risk in menopausal women. The bottom line? Timing, formulation, dose, and even race all play a role in how HRT affects the heart.
The first study, from the SWAN cohort (n=2,737), found that women with vasomotor symptoms who started HRT within 10 years of menopause had a 27% lower CVD risk compared to non-users—but that benefit disappeared, and risk trended upward, for women who started HRT more than 10 years post-menopause. Notably, Black women saw a stronger protective effect (49% lower risk) than white women, who showed no significant benefit.
The second study, using Danish health registry data, found that oral HRT raised the risk of venous thromboembolism, ischemic stroke, and MI—especially with high doses used for more than a year. Transdermal estradiol, however, largely did not carry these same risks.
Key Takeaways:
Why it matters: With the FDA's recent removal of the HRT black-box warning, more women are eligible for treatment—making personalized, evidence-based decision-making more critical than ever.
